Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
30 Nov 2018
New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Product Highlight - Spiolto Respimat

01 May 2018
SPIOLTO RESPIMAT - Tiotropium 2.5 mcg, Olodaterol 2.5 mcg inhalation soln - Boehringer Ingelheim

The Only LAMA/LABA with the active ingredient of SPIRIVA inside (Tiotropium)
Start SPIOLTO RESPIMAT early for your patients
• Starts working within 5 minutes after the first dose1
• Improves lung function, lasts for 24 hours1,2
• Consistently reduces the need for rescue medication beyond SPIRIVA7
• Contains SPIRIVA which has unsurpassed long-term data in EXACERBATION3
• Respimat is designed for deep lung deposition4-6 and all your patients need to do
  is breathe in naturally7

References:
1. SPIOLTO RESPIMAT Summary of Product Characteristics, March 2016
2. Beeh KM. Pulm Pharmacol Ther 2015;32:53-59.
3. Tashkin DP, et al. N Engl J Med 2008;21:159-168.
4. Newman SP, et al. Chest 1998;113:957-963
5. Pitcairn G, et al. J Aerosol Med 2005;18:264-272.
6. Peterson JB, et al. J Aerosol Med Pulm Drug Del 2008;21:159-168.
7. SPIRIVA RESPIMAT Summary of Product Characteristics, Nov 2017

Further information is available in section 3b and mims.com.
Full prescribing information is available upon request.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
30 Nov 2018
New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US.